Real-time enrollment status for this metastatic castration-resistant prostate cancer (mcrpc) clinical trial
Current Status
Recruiting
Checked: August 31, 2026 at 6:46 PM UTC
| NCT Number | NCT07594106 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Phase | PHASE1 |
| Target Enrollment | 265 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Regeneron Pharmaceuticals |
| Last Updated on CT.gov | August 5, 2026 (3 weeks ago) |
As of August 31, 2026: Clinical trial NCT07594106 is currently recruiting participants. This phase1 study for metastatic castration-resistant prostate cancer (mcrpc) is actively seeking new participants at 4 locations across the United States. The study is sponsored by Regeneron Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07594106 is actively recruiting participants as of August 31, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07594106 was last updated 3 weeks ago (August 5, 2026). HelloStudys verifies this status automatically.